In the 3-arm phase II trial called Condor, the authors compared the association of Durvalumab + Tremelimumab, Durvalumab alone, and Tremelimumab in patients affected by recurrent or metastatic HNSCC with low or negative CPS for PD-L1. Here, CD274 is linked to head and neck squamous cell carcinoma.